The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Hereditary Motor Neuronopathies And Neuropathies: Mechanisms Of Neurodegeneration And Potential Modification.
Funder
National Health and Medical Research Council
Funding Amount
$104,664.00
Summary
The aim of the study is to investigate the pathophysiology of motor neuron degeneration in its various acquired and inherited forms. Nerve function will be determined by clinical and neurophysiological assessments in patients. The findings of the study will reveal further insights into the cause and progression of disorders of the motor neuron. This data may function to monitor disease progression, response to potential therapies and lead to the development of further therapeutic strategies.
Flecainide In Amyotrophic Lateral Sclerosis - A Neuroprotective Strategy
Funder
National Health and Medical Research Council
Funding Amount
$593,275.00
Summary
This project will provide clinical trial information related to the potential neuroprotective properties of flecainide in motor neurone disease patients. A potential therapeutic response would provide impetus for a larger scale, multi-centre clinical trial. In addition to providing information about potential mechanisms of neurodegeneration and their treatment, new quantifiable measures will be further developed to objectively monitor MND patients in a clinical trials setting.
Assessment Strategies, Treatments And Risk Factors In Neuropathy And Neuromuscular Disease
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
Neuropathy and neuromuscular disorders provide a major public health challenge. My research efforts are targeted at improving strategies to assess neuropathy and neuromuscular disease, measuring the impact of disease and translating these approaches into clinical trials and clinical practice. The project will identify the best assessment strategies for early detection of nerve damage, determine the impact of nerve disorders in Australia and determine how best to address these disorders.
Studies On Induction Of Antigen Specific T Regulatory Cells To Control Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$353,033.00
Summary
The immune system has natural control mechanisms, called regulatory cells. Our group was the first in the world to correctly identify these cells. There is now a world-wide interest in these cells as they can prevent unwanted immune mediated injury. In autoimmune diseases such as multiple sclerosis, regulatory cells can prevent relapse and progression. This project will identify ways of producing potent specific regulatory cells to control multiple sclerosis and other debilitating neurological d ....The immune system has natural control mechanisms, called regulatory cells. Our group was the first in the world to correctly identify these cells. There is now a world-wide interest in these cells as they can prevent unwanted immune mediated injury. In autoimmune diseases such as multiple sclerosis, regulatory cells can prevent relapse and progression. This project will identify ways of producing potent specific regulatory cells to control multiple sclerosis and other debilitating neurological diseases.Read moreRead less
Gene Discovery And Functional Insights For Neurological And Retinal Disorders
Funder
National Health and Medical Research Council
Funding Amount
$2,163,220.00
Summary
Understanding the genetic drivers of disease is key for the development of disease therapies. Determination of the causal genetic variants in a disorder can be used for future diagnosis, prognostication, and personalised treatment. We have previously identified ~20 novel genes and developed new methods providing genomic diagnoses for 1000s of individuals. In the next five years I will make significant advances in our understanding of what causes diseases such as epilepsy, ataxia and dementia.
Canine Adenovirus-mediated Gene Therapy For CNS Pathology In LSD
Funder
National Health and Medical Research Council
Funding Amount
$490,029.00
Summary
Lysosomal storage disorders (LSD) are inherited diseases that affect about 1 in 7700 Australian children; all share common physical symptoms include heart and breathing difficulties, stiff joints, skeletal deformities, enlarged head, and a characteristic facial appearance. Two-thirds of patients will also develop brain disease. The lysosome is a component of each cell in the human body; its role it is to break down and remove waste from the cell. This involves a series of proteins (enzymes) that ....Lysosomal storage disorders (LSD) are inherited diseases that affect about 1 in 7700 Australian children; all share common physical symptoms include heart and breathing difficulties, stiff joints, skeletal deformities, enlarged head, and a characteristic facial appearance. Two-thirds of patients will also develop brain disease. The lysosome is a component of each cell in the human body; its role it is to break down and remove waste from the cell. This involves a series of proteins (enzymes) that act in sequence. A LSD arises when the lysosome lacks the activity of one protein in this chain. This loss of protein activity means that the waste removal process is impaired. Waste begins to 'store' in the lysosome, clogging the cell and interfering with its usual functions. This gives rise to devastating symptoms that worsen over time as storage increases. Brain disease in LSD has profound effects on the child: mental capacity declines, they become hyperactive and aggressive and progressively lose learned skills (e.g. walking, talking) and control of bodily functions. Artifically made protein is being successfully used to treat some LSD via intravenous injection. However, it cannot access the brain because of a protective barrier that surrounds it. Gene therapy is a method by which we are attempting to overcome this problem. By using a virus called canine adenovirus (or CAV), we plan to produce and insert the missing protein into mice who are deficient in it. CAV will be the protein carrier. CAV is safe in humans and does not have many of the problems associated with some other viruses being tested in gene therapy. We have diagnosed mice who are naturally affected by a LSD with brain disease called MPS IIIA. Their symptoms are similar to that seen in humans, making them ideal for study. CAV vectors are being considered as a long-term treatment for patients who suffer from MPS IIIA and other degenerative brain diseases.Read moreRead less
Cisterna Magna Delivery Of Therapeutic Lysosomal Enzyme To Correct CNS Pathology In Lysosomal Storage Disorders
Funder
National Health and Medical Research Council
Funding Amount
$760,282.00
Summary
Lysosomal storage disorders (LSD) are inherited diseases that affect about 1 in 7700 Australian children; all share common physical symptoms include heart and breathing difficulties, stiff joints, skeletal deformities, enlarged head, and a characteristic facial appearance. Two-thirds of patients will also develop brain disease. The lysosome is a component of each cell in the human body; its role it is to break down and remove waste from the cell. This involves a series of proteins (enzymes) that ....Lysosomal storage disorders (LSD) are inherited diseases that affect about 1 in 7700 Australian children; all share common physical symptoms include heart and breathing difficulties, stiff joints, skeletal deformities, enlarged head, and a characteristic facial appearance. Two-thirds of patients will also develop brain disease. The lysosome is a component of each cell in the human body; its role it is to break down and remove waste from the cell. This involves a series of proteins (enzymes) that act in sequence. A LSD arises when the lysosome lacks the activity of one protein in this chain. The loss of protein activity impairs the waste removal process. Waste begins to 'store', clogging the cell and interfering with its usual functions. This gives rise to devastating symptoms that worsen over time as storage increases. Brain disease in LSD has profound effects on the child: mental capacity declines, they become hyperactive and aggressive and progressively lose learned skills (e.g. walking, talking) and ability to control bodily functions. Artifically made protein is being successfully used to treat some LSD via intravenous injection. However, it is not able to access the brain because of a protective barrier that surrounds it. This project tests a method to deliver protein to the brain to reduce and stop waste build-up. It involves the injection of artificially made protein into the fluid surrounding the brain and spinal cord using techniques being used to treat other diseases. This method is likely to be the quickest way in which we can treat both the body AND the brain of an affected child. We have diagnosed animal models who were born with a LSD with brain disease, called MPS IIIA. Their symptoms are similar to that seen in humans over the course of the disease, making them ideal for study in this project. Success in this project will allow us to advance this treatment to human trials.Read moreRead less
Development Of A Safe And Effective Treatment For Neuropathology In MPS IIIA.
Funder
National Health and Medical Research Council
Funding Amount
$665,320.00
Summary
MPS IIIA is an inherited disorder that results in progressive brain disease in affected children. The disorder cannot be treated at present because it has not been possible to find an effective way to deliver treatment to the brain. This project seeks to evaluate a method to overcome this problem. Findings in this project can be applied to other, similar disorders that affect the brain.
How Do Glycosaminoglycans Promote The Propagation Of Prions?
Funder
National Health and Medical Research Council
Funding Amount
$512,270.00
Summary
The prion diseases are a group of transmissible, neurodegenerative disorders affecting both humans and animals. The most common form in humans is sporadic Creutzfeldt-Jakob disease (CJD), although acquired (variant CJD) and inherited (familial CJD) forms are recognised. Prion diseases are transmissible to the same species by inoculation with, or dietary exposure to, infected tissues. The infectious agent, referred to as a prion , has not been identified at the molecular level. However, a major c ....The prion diseases are a group of transmissible, neurodegenerative disorders affecting both humans and animals. The most common form in humans is sporadic Creutzfeldt-Jakob disease (CJD), although acquired (variant CJD) and inherited (familial CJD) forms are recognised. Prion diseases are transmissible to the same species by inoculation with, or dietary exposure to, infected tissues. The infectious agent, referred to as a prion , has not been identified at the molecular level. However, a major component of purified prions is an abnormal disease associated form of the host encoded prion protein. Understanding how the disease associated form of the prion protein is generated and how host-derived cofactors contribute to its formation will help in our understanding of the infectious nature of these diseases and in the development of effective therapeutic and prophylactic strategies. Glycosaminoglycans are host-derived components of the extracellular matrix that are associated with prion protein plaques found in the brain tissue of patients with prion diseases. Glycosaminoglycans are believed to influence the transmission of prions and the ongoing propagation of infectivity. In this study the importance of glycosaminoglycans in the formation of the disease associated prion protein and the generation of infectivity will be investigated using both cell-free and cell-based models of prion propagation. The understanding gained from this study will be used to develop a high throughput assay that can be used to detect prion infection prior to the development of clinical disease and within a time frame whereby therapeutic intervention may be effective.Read moreRead less